Abstract
In the 21st century, humans are in the battle against a deadly contagious disease COVID-19, first reported in Wuhan, China. Coronavirus disease, designated as COVID-19, is caused by SARS CoV-2 virus from the beta coronavirus family. Although there are no specific anti- viral drugs and vaccines against this pandemic disease, however, many medicines are being repurposed for COVID-19 management but have shown limited success. Traditional medicine systems, since ancient time, were used for their immense efficacy with minimal adverse effects compared to allopathic medicines. Thus, for COVID-19 management, researchers are focusing on traditional medicines from Ayurveda, Chinese medicine, Unani, Siddha, and Homeopathy as adjuvant therapy as per anecdotal data regarding their use in the treatment of infectious disease. In India, all the traditional medicine systems are under AYUSH ministry and government has been highlighting AYSUH medicines for improving immune system against COVID-19. In this review, the authors emphasize on the historical background of AYUSH medicines in the prevention and treatment of infectious diseases and the medicines recommended by the AYUSH ministry for combating COVID-19 as immunity boosters.
Keywords: COVID-19, AYUSH, traditional medicine, SARS CoV-2, ayurveda, homeopathy, siddha, unani.
Graphical Abstract
Current Traditional Medicine
Title:AYUSH Preparations as Immunity Booster in the Management of SARS - CoV-2: A Review
Volume: 7 Issue: 4
Author(s): Suneel Prajapati*, Mahima Sharma, Arun Kumar, Ashish Tripathi, GV Narasimha Kumar, Shilpi Singh, Monika Singh, Digvijay Verma and Pankaj Gupta
Affiliation:
- Central Forensic Science Laboratory, Krishna Complex, Kharadi, Pune, Maharashtra,India
Keywords: COVID-19, AYUSH, traditional medicine, SARS CoV-2, ayurveda, homeopathy, siddha, unani.
Abstract: In the 21st century, humans are in the battle against a deadly contagious disease COVID-19, first reported in Wuhan, China. Coronavirus disease, designated as COVID-19, is caused by SARS CoV-2 virus from the beta coronavirus family. Although there are no specific anti- viral drugs and vaccines against this pandemic disease, however, many medicines are being repurposed for COVID-19 management but have shown limited success. Traditional medicine systems, since ancient time, were used for their immense efficacy with minimal adverse effects compared to allopathic medicines. Thus, for COVID-19 management, researchers are focusing on traditional medicines from Ayurveda, Chinese medicine, Unani, Siddha, and Homeopathy as adjuvant therapy as per anecdotal data regarding their use in the treatment of infectious disease. In India, all the traditional medicine systems are under AYUSH ministry and government has been highlighting AYSUH medicines for improving immune system against COVID-19. In this review, the authors emphasize on the historical background of AYUSH medicines in the prevention and treatment of infectious diseases and the medicines recommended by the AYUSH ministry for combating COVID-19 as immunity boosters.
Export Options
About this article
Cite this article as:
Prajapati Suneel *, Sharma Mahima, Kumar Arun , Tripathi Ashish , Kumar Narasimha GV , Singh Shilpi , Singh Monika, Verma Digvijay and Gupta Pankaj , AYUSH Preparations as Immunity Booster in the Management of SARS - CoV-2: A Review, Current Traditional Medicine 2021; 7 (4) : e190122188623 . https://dx.doi.org/10.2174/2215083806999201202151923
DOI https://dx.doi.org/10.2174/2215083806999201202151923 |
Print ISSN 2215-0838 |
Publisher Name Bentham Science Publisher |
Online ISSN 2215-0846 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
SARS-CoV-2: Origin, Pathogenesis and Therapeutic Interventions
Coronaviruses New Coronavirus Outbreak
Current Pharmaceutical Analysis Drug Design Targeting the Main Protease, the Achilles Heel of Coronaviruses
Current Pharmaceutical Design Research/Review: Insights into the Mutation-Induced Dysfunction of Arachidonic Acid Metabolism from Modeling of Human CYP2J2
Current Drug Metabolism Improving the Stability of Aptamers by Chemical Modification
Current Medicinal Chemistry A Review on Remdesivir: A Broad-spectrum Antiviral Molecule for Possible COVID-19 Treatment
Mini-Reviews in Medicinal Chemistry Pharmacological, Immunological, and Gene Targeting of the Renin-Angiotensin System for Treatment of Cardiovascular Disease
Current Pharmaceutical Design COVID-19 and Alcohol Misuse: A Case Report
Infectious Disorders - Drug Targets COVID-19 and the Challenges of Chemotherapy: The Failure Case of Hydroxychloroquine in the Clinical Treatment of SARS-CoV-2 Infection
Coronaviruses Antiviral Activity of Phytochemicals: A Comprehensive Review
Mini-Reviews in Medicinal Chemistry Editorial (Thematic Issue: Immunophilins, Protein Chemistry and Cell Biology of a Promising New Class of Drug Targets – Part II)
Current Molecular Pharmacology Virtual Screening, Molecular Docking and <i>In silico</i> ADME-Tox Analysis for Identification of Potential Main Protease (Mpro) Enzyme Inhibitors
Anti-Infective Agents Silybin B and Cianidanol Inhibit M<sup>pro</sup> and Spike Protein of SARS-CoV-2: Evidence from in silico Molecular Docking Studies
Current Pharmaceutical Design Treatment of Disorders Characterized by Reversible Airway Obstruction in Childhood: are Anti-cholinergic Agents the Answer?
Current Pharmaceutical Design A Further Step Toward an Optimal Ensemble of Classifiers for Peptide Classification, a Case Study: HIV Protease
Protein & Peptide Letters Comparison of Clinical Characteristics, Laboratory Findings and Imaging Manifestations of COVID-19 in Sulfur Mustard-exposed Survivors and Others: a Case-control Study
Current Drug Therapy Survival Analysis Based on the Siddha Body Constitution of Asymptomatic SARS-CoV-2 Patients Under Integrative Management of Hydroxychloroquine (HCQ) and Kaba Sura Kudineer (KSK): A Retrospective Cross-sectional Case Series from Tirupati
Current Traditional Medicine Gibbs Sampling Shows Possibilities of B-Cell Epitope Signatures
Protein & Peptide Letters Ocular COVID-19: Eyes as a Reservoir to Conceal and Spread SARSCoV- 2
Infectious Disorders - Drug Targets Therapeutic Agents for COVID-19: an Overview
Current Drug Therapy